10X Genomics (TXG) Stock Rated Buy Following Acquisition Announcement

Canaccord has reiterated its Buy rating on 10X Genomics (TXG) stock after the company's recent acquisition. The acquisition is expected to enhance the company's product offerings and market presence. Analysts forecast that this strategic move could lead to increased revenue growth for TXG. The market may respond positively to this acquisition as it positions 10X Genomics for future expansion.